Search research articles
Contact Us
Filters
Showing results (71-80 of 103) with videos related to
Page
of 11
Sort By:
BMC Anesthesiology
|
December 4, 2014
An evaluation of POSSUM and P-POSSUM scoring in predicting post-operative mortality in a level 1 critical care setting
Sarah Scott, Jonathan N Lund, Stuart Gold, et al.
Journal of Environmental Monitoring : JEM
|
August 27, 2005
The Mid-Canada Radar Line and First Nations' people of the James Bay region, Canada: an evaluation using log-linear contingency modelling to analyze organochlorine frequency data
Leonard J S Tsuji, Bruce C Wainman, Ian D Martin, et al.
The International Journal on Drug Policy
|
April 7, 2023
Assessing options for poppers policy in Canada: A call to action for evidence-based policy reform
Cameron Schwartz, Kiffer Card, Richard Elliott, et al.
Molecular Cancer Therapeutics
|
February 13, 2015
Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways
Marieke Aarts, Ilirjana Bajrami, Maria T Herrera-Abreu, et al.
The EMBO Journal
|
April 5, 2008
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
Nicholas C Turner, Christopher J Lord, Elizabeth Iorns, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 23, 2009
Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs)
Terry Panchal, Nick Bailey, Mark Bamford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 25, 2013
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency
Yuqiao Shen, Farah L Rehman, Ying Feng, et al.
Oncotarget
|
June 2, 2015
Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway
Annalisa Conti, Maria Teresa Majorini, Richard Elliott, et al.
Cancer Cell
|
February 5, 2008
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer
Elizabeth Iorns, Nicholas C Turner, Richard Elliott, et al.
Molecular Cell
|
November 26, 2008
Inactivation of effector caspases through nondegradative polyubiquitylation
Mark Ditzel, Meike Broemer, Tencho Tenev, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 103) with videos related to
Sort By:
Page
of 11
BMC Anesthesiology
|
December 4, 2014
An evaluation of POSSUM and P-POSSUM scoring in predicting post-operative mortality in a level 1 critical care setting
Sarah Scott, Jonathan N Lund, Stuart Gold, et al.
Journal of Environmental Monitoring : JEM
|
August 27, 2005
The Mid-Canada Radar Line and First Nations' people of the James Bay region, Canada: an evaluation using log-linear contingency modelling to analyze organochlorine frequency data
Leonard J S Tsuji, Bruce C Wainman, Ian D Martin, et al.
The International Journal on Drug Policy
|
April 7, 2023
Assessing options for poppers policy in Canada: A call to action for evidence-based policy reform
Cameron Schwartz, Kiffer Card, Richard Elliott, et al.
Molecular Cancer Therapeutics
|
February 13, 2015
Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways
Marieke Aarts, Ilirjana Bajrami, Maria T Herrera-Abreu, et al.
The EMBO Journal
|
April 5, 2008
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
Nicholas C Turner, Christopher J Lord, Elizabeth Iorns, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 23, 2009
Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs)
Terry Panchal, Nick Bailey, Mark Bamford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 25, 2013
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency
Yuqiao Shen, Farah L Rehman, Ying Feng, et al.
Oncotarget
|
June 2, 2015
Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway
Annalisa Conti, Maria Teresa Majorini, Richard Elliott, et al.
Cancer Cell
|
February 5, 2008
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer
Elizabeth Iorns, Nicholas C Turner, Richard Elliott, et al.
Molecular Cell
|
November 26, 2008
Inactivation of effector caspases through nondegradative polyubiquitylation
Mark Ditzel, Meike Broemer, Tencho Tenev, et al.
Page
of 11